These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 35306635)

  • 61. The TAS Test project: a prospective longitudinal validation of new online motor-cognitive tests to detect preclinical Alzheimer's disease and estimate 5-year risks of cognitive decline and dementia.
    Alty J; Bai Q; Li R; Lawler K; St George RJ; Hill E; Bindoff A; Garg S; Wang X; Huang G; Zhang K; Rudd KD; Bartlett L; Goldberg LR; Collins JM; Hinder MR; Naismith SL; Hogg DC; King AE; Vickers JC
    BMC Neurol; 2022 Jul; 22(1):266. PubMed ID: 35850660
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Diagnostic Accuracy of Memory Measures in Alzheimer's Dementia and Mild Cognitive Impairment: a Systematic Review and Meta-Analysis.
    Weissberger GH; Strong JV; Stefanidis KB; Summers MJ; Bondi MW; Stricker NH
    Neuropsychol Rev; 2017 Dec; 27(4):354-388. PubMed ID: 28940127
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Biomarkers for the Diagnosis of Alzheimer's Disease in Clinical Practice: The Role of CSF Biomarkers during the Evolution of Diagnostic Criteria.
    Dulewicz M; Kulczyńska-Przybik A; Mroczko P; Kornhuber J; Lewczuk P; Mroczko B
    Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955728
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Multivariate protein signatures of pre-clinical Alzheimer's disease in the Alzheimer's disease neuroimaging initiative (ADNI) plasma proteome dataset.
    Johnstone D; Milward EA; Berretta R; Moscato P;
    PLoS One; 2012; 7(4):e34341. PubMed ID: 22485168
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Is cerebral microbleed prevalence relevant as a biomarker in amnestic mild cognitive impairment and mild Alzheimer's disease?
    Rabelo AG; Teixeira CV; Magalhães TN; Carletti-Cassani AFM; Amato Filho AC; Joaquim HP; Talib LL; Forlenza O; Ribeiro PA; Secolin R; Lopes-Cendes I; Cendes F; Balthazar ML
    Neuroradiol J; 2017 Oct; 30(5):477-485. PubMed ID: 28714354
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [New diagnostic guidelines for Alzheimer's disease by NIA/AA].
    Ihara R
    Nihon Rinsho; 2016 Mar; 74(3):386-94. PubMed ID: 27025074
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Plasma Lipocalin 2 in Alzheimer's disease: potential utility in the differential diagnosis and relationship with other biomarkers.
    Hermann P; Villar-Piqué A; Schmitz M; Schmidt C; Varges D; Goebel S; Bunck T; Lindemann H; Bogner C; Santana I; Baldeiras I; Riggert J; Zerr I; Llorens F
    Alzheimers Res Ther; 2022 Jan; 14(1):9. PubMed ID: 35027079
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Disease tracking markers for Alzheimer's disease at the prodromal (MCI) stage.
    Drago V; Babiloni C; Bartrés-Faz D; Caroli A; Bosch B; Hensch T; Didic M; Klafki HW; Pievani M; Jovicich J; Venturi L; Spitzer P; Vecchio F; Schoenknecht P; Wiltfang J; Redolfi A; Forloni G; Blin O; Irving E; Davis C; Hårdemark HG; Frisoni GB
    J Alzheimers Dis; 2011; 26 Suppl 3():159-99. PubMed ID: 21971460
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Renovating Alzheimer's: "constructive" reflections on the new clinical and research diagnostic guidelines.
    George DR; Qualls SH; Camp CJ; Whitehouse PJ
    Gerontologist; 2013 Jun; 53(3):378-87. PubMed ID: 22936533
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Development and validation of an interpretable deep learning framework for Alzheimer's disease classification.
    Qiu S; Joshi PS; Miller MI; Xue C; Zhou X; Karjadi C; Chang GH; Joshi AS; Dwyer B; Zhu S; Kaku M; Zhou Y; Alderazi YJ; Swaminathan A; Kedar S; Saint-Hilaire MH; Auerbach SH; Yuan J; Sartor EA; Au R; Kolachalama VB
    Brain; 2020 Jun; 143(6):1920-1933. PubMed ID: 32357201
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage.
    Vos SJ; Verhey F; Frölich L; Kornhuber J; Wiltfang J; Maier W; Peters O; Rüther E; Nobili F; Morbelli S; Frisoni GB; Drzezga A; Didic M; van Berckel BN; Simmons A; Soininen H; Kłoszewska I; Mecocci P; Tsolaki M; Vellas B; Lovestone S; Muscio C; Herukka SK; Salmon E; Bastin C; Wallin A; Nordlund A; de Mendonça A; Silva D; Santana I; Lemos R; Engelborghs S; Van der Mussele S; ; Freund-Levi Y; Wallin ÅK; Hampel H; van der Flier W; Scheltens P; Visser PJ
    Brain; 2015 May; 138(Pt 5):1327-38. PubMed ID: 25693589
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Relationship of dementia screening tests with biomarkers of Alzheimer's disease.
    Galvin JE; Fagan AM; Holtzman DM; Mintun MA; Morris JC
    Brain; 2010 Nov; 133(11):3290-300. PubMed ID: 20823087
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Interpreting Biomarker Results in Individual Patients With Mild Cognitive Impairment in the Alzheimer's Biomarkers in Daily Practice (ABIDE) Project.
    van Maurik IS; Zwan MD; Tijms BM; Bouwman FH; Teunissen CE; Scheltens P; Wattjes MP; Barkhof F; Berkhof J; van der Flier WM;
    JAMA Neurol; 2017 Dec; 74(12):1481-1491. PubMed ID: 29049480
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Current State of Digital Biomarker Technologies for Real-Life, Home-Based Monitoring of Cognitive Function for Mild Cognitive Impairment to Mild Alzheimer Disease and Implications for Clinical Care: Systematic Review.
    Piau A; Wild K; Mattek N; Kaye J
    J Med Internet Res; 2019 Aug; 21(8):e12785. PubMed ID: 31471958
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Prediction of Alzheimer's dementia].
    Jessen F; Dodel R
    Nervenarzt; 2014 Oct; 85(10):1233-7. PubMed ID: 25231823
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Connected Speech Deficit as an Early Hallmark of CSF-defined Alzheimer's Disease and Correlation with Cerebral Hypoperfusion Pattern.
    Mazzon G; Ajčević M; Cattaruzza T; Menichelli A; Guerriero M; Capitanio S; Pesavento V; Dore F; Sorbi S; Manganotti P; Marini A
    Curr Alzheimer Res; 2019; 16(6):483-494. PubMed ID: 31057108
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Interest of biological biomarkers in the diagnostic approach of neurocognitive disorders in the elderly.
    Lilamand M; Hourregue C; Paquet C
    Rev Neurol (Paris); 2020 Nov; 176(9):677-683. PubMed ID: 32169325
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Clinical validity of medial temporal atrophy as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework.
    Ten Kate M; Barkhof F; Boccardi M; Visser PJ; Jack CR; Lovblad KO; Frisoni GB; Scheltens P;
    Neurobiol Aging; 2017 Apr; 52():167-182.e1. PubMed ID: 28317647
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Advances in retina imaging as potential biomarkers for early diagnosis of Alzheimer's disease.
    Zhang Y; Wang Y; Shi C; Shen M; Lu F
    Transl Neurodegener; 2021 Feb; 10(1):6. PubMed ID: 33517891
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Awareness disorders in Alzheimer's disease and in mild cognitive impairment].
    Jacus JP; Dupont MP; Herades Y; Pelix C; Large H; Baud M
    Encephale; 2014 Apr; 40(2):180-7. PubMed ID: 24630532
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.